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Background: HIV and Non communicable diseases (NCDs) are major problem of public health importance in
developing countries. This study was conducted to explore and establish information on the magnitude,
distribution of NCDs risk factors among people living with HIV (PLWHIV) which is scarce in Tanzania.
Method: A cross sectional study was conducted to PLWHIV from 12 care and treatment clinics in Dar es Salaam
and Mbeya regions from October 2011 to February 2012. Data on demographic characteristics, NCD risk factors
including behavioral, biochemical tests and physical measurements was collected from PLWHIV.
Results: Of 754 PLWHIV recruited, 671(89.0%) consented to participate in the study and 354/671(52.8%) were on
antiretroviral therapy (ART). The following NCD risk factors: raised blood levels of low density lipoprotein (61.3% vs
38.7%, p < 0.001) total cholesterol (TC) (71.6% vs 28.4%, p < 0.001) and triglyceride (67.0% vs 33.0%, p = 0.001) as
well as overweight/obesity (61.1% vs 38.9%, p = 0.010), abnormal waist circumference (61.7% vs 38.3%, p < 0.001)
and being aged >40 years (63.3% vs 36.7%, p < 0.001) were more prevalent among PLWHIV on ART than ART naïve.
The prevalence of Diabetes mellitus among PLWHIV was 4.2% and was slightly high among those ART naïve (4.7%
vs 3.7%). The prevalence of hypertension was 26.2% and was high among those on ART (30.0% vs 21.9%, p =
0.010). Being aged >40 years (AOR = 2.52, 95% CI 1.37-4.63), abnormal waist circumference (AOR = 2.37 95% CI
1.13-5.00), overweight/obesity (AOR = 2.71, 95% CI 1.26-5.84) and male sex (AOR = 1.17, 1.02-4.20) were the
predictors of hypertension among patients on ART while raised TC (AOR = 1.47 (1.01-2.21) and being aged >40
years (AOR = 3.42, 95% CI 2.06-5.70) were predictors for hypertension among ART naïve patients.
Conclusion: This study has revealed that the magnitude of NCD risk factors is significantly higher among PLWHIV
on ART than those not on ART. Initiating and strengthening of interventions for minimizing preventable NCD risks
should be considered when initiating ART among PLWHIV. Regular monitoring of NCD risk factors is of paramount
importance among ART patients.
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According to the recent survey, the prevalence of HIV
among sexual active aged 15–49 years in Tanzania; is
5.1% [1]. The prevalence has consistently continued to
be high in urban than rural settings [1-3]. However, the
overall HIV prevalence among individuals aged 15–49
years has declined from 7% (2003–04) to 6% (2007–08)
to 5.1% (2011–12) [1-3]. The prevalence varied greatly
across regions, ranging from 2.0% to 16.0% (2007–08)
and from 1.5% to 14.8% (2011–12) [1,3]. The declining
of the overall HIV prevalence has been associated with
behavioral change, availability and improved accessibility
of ART services and biomedical interventions programs
targeting both the general population and specific vul-
nerable groups [4].
Studies have reported an increased risk of cardiovascular
disease (CVDs) among people living with HIV (PLWHIV).
This is due to the linkage between HIV/AIDS and non-
communicable diseases (NCDs) [5-7]. The linkage is
either due to direct effects of HIV or indirectly by anti-
retroviral therapy (ART) regimens. HIV can directly
damage the cells of blood vessels and contribute to ath-
erosclerosis, or hardening of the arteries [8]. This is due to
inflammation induced by HIV infection or its associated
proteins which may promote atherosclerosis and forma-
tion of high-risk plaque, thus increasing the risk of myo-
cardial infarction and stroke [9-11]. Several studies have
found that the various drugs included in ART regimens
have different effects on patients’ cholesterol and fatty acid
balance [9,11]. The therapy seems to affect the risks of
heart diseases by increasing cholesterol levels and chan-
ging fat distribution, particularly increasing abdominal fat
[12-14]. For example nucleoside reverse transcriptase in-
hibitors (NRTIs), stavudine mainly causes increased blood
levels of triglycerides (TG), low density lipoprotein choles-
terol (LDL-C) and total cholesterol (TC) [15,16]. All of the
protease inhibitors (PIs) except atazanavir have been asso-
ciated with hyperlipidemia, for example ritonavir-boosted
PIs, cause elevations of LDL, TC and TGs and a decrease
in high density lipoprotein cholesterol (HDL-C) [17,18].
The prevalence of hypertriglyceridemia and hypercholes-
terolemia among PLWHIV on PI-based antiretroviral regi-
men has been documented to 38.2% and 25% respectively
and it appeared to be dose- and probably time-related
[19]. Overweight and obesity as other risk factors for
CVDs has been reported to be common morphological al-
teration among PLWHIV on ART [20]. Being overweight
or obese is well known traditional risk factor associated
with raises blood pressure (BP) and dyslipidemia [21].
A study conducted in Nigeria revealed an increase of
prevalence of hypertension from 26% to 31.7% after two
years of being initiated on ART [22]. In Botswana, the
prevalence of raised BP was twice as much among
PLWHIV compared to the general population [23]. Theincidence of diabetes mellitus is fourfold among HIV-
infected men on ART compared to HIV negative men
[24]. HIV infection has also been associated with inci-
dence of stroke, for example, the HIV prevalence among
patients with stroke in Malawi was 48% [25] and in
Tanzania was 20.9% and the mean age was lower among
stoke patients with HIV infection compared to their
HIV negative counterparts [26].
Kidney disease is an important contributor to HIV/
AIDS related morbidity and mortality. As the life expect-
ancy of HIV-infected patients increases with the use of
ART, chronic medical conditions such as renal failure
are increasingly prevalent [27]. In addition, the risk of
type2 diabetes mellitus is increased among PLWHIV and
is associated with cumulative exposure to ART [24,28].
Furthermore, in many areas dietary counseling for HIV
is tailored towards increased calorie intake and weight
gain, hence, majority consume fatty diets to increase
their weight; coupled with ART induced dyslipidemia,
these patients are at an increased risk of an uncon-
trolled weight gain which is a risk factor for NCDs [29].
Due to the evidences reported elsewhere much informa-
tion related to NCDs to PLWHIV in Tanzania is needed
to inform various HIV programs. The scientific evidence
to substantiate the foregoing discussion in linking oc-
currence of NCDs in HIV patients on ART is limited
in Tanzania. The situation on the magnitude and NCD
risk factors among PLWHIV in Tanzania is not known
hence posing challenges for designing, planning and
implementing possible interventions to the affected
population. Therefore, this study was proposed to ob-
tain findings to inform policy on the magnitude and risk
factors of NCDs among PLWHIV for strengthening in-
terventions to prevent morbidity and mortality in pa-
tients which might be accelerated by co-morbidities
(NCD and HIV).
Methods
Study area, design and population
A cross-sectional study was conducted in two purpose-
fully selected regions namely Mbeya and Dar es Salaam.
The former representing rural settings and the latter is
the largest urbanized city in Tanzania. The two regions
had the largest number of PLWHIV enrolled in care and
treatment clinics (CTCs) in the country [30]. PLWHIV
aged 18 years and above attending 12 CTCs in these re-
gions were interviewed using a structured questionnaire.
Anthropometric measurements and biochemical profile
were also assessed. The study population was both
PLWHIV on ART and those not on ART.
Sample size calculation
To calculate sample size, we used prevalence (P) of Dia-
betes Mellitus among PLWHIV admitted with stroke at
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prevalence of patients with no diabetes (as our 1-P) was
88.9% [26]. Using randomly sampling formula, with the
following parameters: Z = the level of statistical signifi-
cant set up at the level of 95% confidence interval (1.96)
and (e) = likelihood error (2.5%) then the minimum
sample size obtained was 602. To take care of non-
responders, 20% non response was considered during
sample size calculation; leading to a minimum sample
size of PLWHIV attending CTC services to be include
in the study to be 754.
Sampling procedures
Two districts were randomly selected from each region:
Ilala and Kinondoni districts from Dar es Salaam and
Kyela and Rungwe districts from Mbeya region. A list of
the CTCs arranged by strata/level (dispensary, health
center and hospital) was made available per site and
from each stratum one CTC was randomly selected
using a randomly selection Table [31]. A total of 12
CTCs (three from each district) were therefore selected.
Then, separate lists of PLWHIV on ART and those not
on ART were made for each of these CTCs. The lists
provided a sampling frame for both PLWHIV on ART
and those not on ARTs. The proportion allocation statis-
tical technique which is described by randomly selection
table [31] was used to obtain sub-sample from different
levels of health facilities i.e. dispensaries, health centers
and hospitals from each district. The names of CTCs
from each district with respective sub actual sample size
in the brackets are as follows: − Kinondoni district were
Mwananyamala (91), Sinza (92) and Mwenge (3); Ilala
district were Amana (95), Buguruni (44) and Mnazim-
moja (28); Rungwe district Tukuyu(149), Masukulu(5)
and Mwakaleli (14) and from Kyela district were Kyela
(155), Njisi(9) and Ngonga(6).
Ethical issue
Protocol for this study was reviewed and approved by
the Medical Research and Coordinating Committee
(MRCC) of the National Institute for Medical Research
(NIMR)-Tanzania (certificate No NIMR/HQ/R.8a/Vol.
IX/1130). The study involved PLWHIV attending CTCs
which are the clinics dedicated for offering services to
PLWHIV only. The study team (which was formed
mainly by medical personnel) worked closely with the
CTC administration. Each study subject, was individually
and privately informed on the aim and purpose of the
study, risks and benefits of participating in the study,
and that, his/her participation was purely voluntary, and
there would be no any negative effect that she/he will
get for not consenting to participate in the study. All
questions and queries were satisfactorily answered and
clarified before consenting through signing a writteninformed consent form. Confidentiality was maintained
throughout the study period. Apart from the research
team and the CTC staff, data was not accessed by any
other person. Each study participant was informed of
his/her physical assessment and biochemical test results
and given appropriate health education. In addition,
every participant was given a hard copy of the feedback
form for both physical measurements and biochemical
tests performed. If the study participant was found to
have either NCD or NCD risk factor, the information
was communicated to the CTC in-charge for further
evaluation, assessment, management and monitoring ac-
cording to the WHO guidelines [32].
Data collection
A structured questionnaire with both closed and open-
ended questions was adopted from STEPs survey tool.
Adopted tool was translated from English to Swahili
language which is the national and familiar language to
the intended subjects. The questionnaire was back-
translated to English to see if the intended message was
maintained. Before commencing the actual data collec-
tion a three days training was conducted to the data col-
lectors and majority were medical personnel; in day one
for familiarizing the study aims and protocol, day two
for piloting the tool and day three for refining the tool.
The refined tool was used for data collection. Informa-
tion on demographic characteristics, NCD risk factors,
anthropometric and biochemical measurements such as
blood glucose, lipid profile was collected from each
study subject. At every CTC, an equal number of study
subjects on ART and those not on ART were obtained at
exit point i.e. dispensing table. All physical measurement
data (weight, height, waist circumference and blood
pressure) was collected by the research team members
while the samples for biochemical test (TC, HDL, LDL,
TG and FBG) were collected and analyzed by qualified
laboratory technicians.
Physical measurements
Blood pressure (BP) measurements
Blood pressure was measured while patients were in a
sitting position, using an M4 Omron® automatic blood
pressure device. The blood pressure reading was consist-
ently taken from the left arm, three times at 3 minutes
interval [33]. The average of the two last readings was
estimated and used in the analysis. High blood pressure
was classified as BP of ≥140/90 mmHg.
Weight measurement
Weight measurement was taken using a SECA® weighing
scale on a flat hard surface. Patients were instructed to
remove any heavy clothing (such as coats) and shoes
and stand still on the weighing scale, with hands by their
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ing to manufacturer’s instructions.
Height measurement
Height was measured with a SECA® stadiometer, while a
patient is facing directly ahead. Patients were instructed
to remove their shoes, caps or head scarfs, keep their
feet together, and stand with their arms by the sides.
Measurement was taken with heels, buttocks and upper
back in contact with the stadiometer.
Body mass index (BMI)
The BMI was calculated as weight (in Kilograms) divided
by height squared (m2). The BMI results were catego-
rized as: obesity if the BMI was ≥30 kg/m2; Overweight
if the BMI was > 25 but < 30 kg/m2, and normal if the
BMI was between 18-25 kg/m2 and underweight if
below 19 kg/m2 [34].
Waist circumference
The measurement was made at the approximate midpoint
between the lower margin of the last palpable rib and the
top of the iliac crest as per WHO guidelines [35]. We used
the European cut off to interpret the waist circumference
measurements as per World Health Organizations (WHO)
and International Diabetes Federation (IDF) recommen-
dations. According to the above guidelines the range
of abnormal waist circumference of male and female
are >94 cm and >80 cm respectively [36,37].
Laboratory tests
In addition to the questionnaires and anthropometric mea-
surements, the study subjects were requested to return to
the clinics to provide fasting blood samples for blood glu-
cose and cholesterol measurements in the following morn-
ing. Patients were provided with return transport fare
Tanzanian Shillings 3,000/= (equivalent to 2 US$) to facili-
tate the return visits. All patients were provided with a
feedback of their results and advised accordingly.
Fasting blood glucose measurement
Patients were instructed to fast for at least 8 hours be-
fore the test. All tests were performed by trained labora-
tory technicians. Blood sample was taken by finger prick
(capillary) and measured using Hemoque® 201 analyzer.
Diagnosis of diabetes mellitus was done according to
WHO classification [38].
Lipid profile estimations
Blood was taken for lipid measurements namely includ-
ing: High Density Lipoprotein Cholesterol (HDL-C),
Low Density Lipoprotein Cholesterol (HDL-C), Total
Cholesterol (TC), and triglycerides Cholesterol (TG-C).
Blood sample of 4mls for lipid profile were taken from avenipuncture and placed in a plain vacutainer. Blood
was kept at room temperature and was analyzed the
same day, within hours of sample collection. Samples
were analyzed using fully automated biochemistry ana-
lyzers by the direct end point enzymatic method.
Analysis
Data collected was double entered and coded using Epi-
data Version 3.1. Data was then exported to SPSS version
18 for Windows (SPSS Inc, Chicago, IL, USA) and STATA
version 12 (STATA Corp Inc., TX, USA) for cleaning and
analysis. Pearson Chi square statistics test was used to
compare group differences for categorical variables. Asso-
ciations and relationships were considered statistically sig-
nificant if p < 0.05. Logistic regression was used for
modeling multiple risks for hypertension and it was also
intended for the diabetes mellitus; however, analysis for
diabetes mellitus was not conducted because of the col-
lected small number of diabetes cases. Crude and Ad-
justed Odds Ratios (OR) with 95% confidence intervals
(CI) were reported. Variables that were considered signifi-
cant in then univariate analysis were analyzed using multi-
variate analysis. Backward stepwise selection with removal
testing was used, which based on probability of the likeli-
hood ratio statistic. The significance level of a likelihood
ratio statistic was compared to a cut-off value of 0.1.
Twelve variables were considered in the initial model in
each group. For the patients on ART only four out of six
variables which were significant in the univariate analysis
were considered significant in the multivariate analysis
based on the p-value for likelihood ratio (−2 Log likeli-
hood = 45.97, p = 0.001) with common odds ratio of 3.34
(2.00-5.58). While for the non ART patients only two out
of four variables which were significant in the univariate
analysis were significant in multivariate analysis based on
the p-value for likelihood ratio (−2 Log likelihood = 24.19,
p < 0.001) with common odds ratio of 2.37(1.31-4.31).
Results
General characteristics
The demographic characteristics of the study partici-
pants are shown in [Table 1]. A total of 754 PLWHIV
were recruited for the study, however, 671(89.0%) partic-
ipants consented and participated in the study. Patients
on ART and female constituted 52.8% (354/671) and
70.5% (473/671) of the study participants respectively.
The overall mean age of the respondents in years (SD)
was 38.7 (10.1). The mean age of males was 42.5(11.1)
and female was 37.1(9.2). The mean age for patients on
ART was 40.6(9.3) and 36.7(10.6) for those not on ART.
Age groups 18–34 and 35–44, constituted a majority of
study population, each forming 37.4%. Three quarters of
the respondents had attained primary level of education
and more than half (53.0%) were married.
Table 1 Social and demographic characteristics of
PLWHIV by ART status (n = 671)
Characteristics Both, n (%) Patients on
ART, n (%)
Patients not on
ART, n (%)
Response rate 671/754(89.0) 354/377(93.9) 317/377(84.1)
Region
Dar es Salaam 336(50.1) 179(50.6) 157(49.5)
Mbeya 335(49.9) 175(49.4) 160(50.5)
Age group
18-34 251(37.4) 100(28.2) 151(47.6)
35-44 251(37.4) 147(41.5) 104(32.8)
45-54 117(17.4) 75(21.2) 42(13.2)
55+ 52(7.7) 32(9.0) 20(6.3)
Sex
Male 198(29.5) 114(32.2) 84(26.5)
Female 473(70.5) 240(67.8) 233(73.5)
Education level
No formal education 84(12.5) 44(12.4) 40(12.6)
Adult education 3(0.4) 2(0.6) 1(0.3)
Primary education 503(75.0) 265(74.9) 238(75.1)
Secondary education 69(10.3) 37(10.5) 32(10.1)
College/University 12(1.8) 6(1.7) 6(1.9)
Marital status
Single 39(12.3) 83(12.4) 44(12.4)
Married 168(53.0) 319(47.5) 151(42.7)
Separated 30(9.5) 74(11.0) 44(12.4)
Divorced 10(3.2) 17(2.5) 7(2.0)
Widow/Widower 53(16.7) 136(20.3) 83(23.4)
Cohabiting 17(5.4) 42(6.3) 25(7.1)
Occupation
Farmer 234(34.9) 115(35.5) 119(39.5)
Self-employed 224(33.4) 134(41.4) 90(29.9)
Employed 76(11.3) 36(11.1) 40(13.3)
Others 91(13.6) 39(12.0) 52(17.3)
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Prevailing risk factors for NCD among the participants in-
cluded: low blood levels of HDL (71.9%), consumption of
fruits or vegetables below the recommended standards
(70.0%), poor participation on vigorous physical activities
(including running, cycling, digging, manual construction
works, brisk walking) (47.8%), abnormal waist circumference
(46.6%) and raised blood levels of LDL (42.9%) [Table 2].
Association between the magnitudes of NCD risks factors
and ART use
Low blood levels of HDL and current alcohol drinking
habit was significantly more observed among partici-
pants not on ART compared to those on ART (56.4% vs43.6%, p < 0.001) and (52.0% vs 48.0%, p = 0.048) re-
spectively. The proportion of patients on ART with
raised blood levels of LDL was high compared to those
not on ART (61.3% vs 38.7%, p < 0.001). Prevalence of
raised blood levels of TC was almost three times among
participants on ART compared to those not on medica-
tions (71.6% vs 28.4%, p < 0.001). The proportion of pa-
tients on ART with raised Triglyceride and who were
overweight/obese was significantly high compared to
those not on ART (67.0% vs 33.0%, p = 0.001) and
(61.1% vs 38.9%, p = 0.010) respectively. Patients on
ART were older compared to the counterpart group
(those aged >40 yrs, 63.3% vs those aged ≤40 yrs 36.7%,
p < 0.001) and patients on ART with abnormal waist cir-
cumference were almost two times than the counterpart
group (61.7% vs 38.3%, p < 0.001) [Table 2].
Magnitude of NCD co-morbidities among PLWHIV
Hypertension
The prevalence of hypertension (blood pressure of ≥140/
90 mmHg measured during the study period or previously
diagnosed with hypertension) among study participants
was 26.2% (175/668). The prevalence of hypertension was
significantly higher among those on ART than those not on
ART (30.0% vs 21.9%, p = 0.011). Further analysis i.e. uni-
variate and multivariate logistic regression analysis was con-
ducted to establish the relationship between the prevalence
of raised BP and the risk factors of the disease [Table 3].
Diabetes mellitus (DM)
The prevalence of Diabetes mellitus (DM) i.e. fasting
blood glucose (FBG) of ≥6.1 mmol/l (measured during the
study period or previously diagnosed with DM among
PLWHIV was 4.2% (28/671). The prevalence of DM
among participants on ART and not on ART was 3.7%
and 4.7% respectively.
Multivariate analysis for multiple risk factors for
hypertension by ART use
Univariate and Multivariate analysis on the risk factors for
hypertension by ART status among PLWHIV is shown on
[Table 3]. With multiple regression analysis, age above
40 years (AOR= 3.42, 95% CI 2.06-5.70) and raised blood
TC (AOR= 1.47 (1.01-2.21) were the risk factors that
predicted the prevalence of hypertension among partici-
pants not on ART. On the other hand, age above 40 years
(AOR= 2.52, 95% CI 1.37-4.63), abnormal waist circumfer-
ence (AOR= 2.37 95% CI 1.13-5.00), overweight/obesity
(AOR= 2.71, 95% CI 1.26-5.84), and a male sex (AOR= 1.17,
1.02-4.20) predicted the prevalence among those on ART.
Discussion
The most common NCD risk factors observed among
both groups (on ART and not on ART) participants of
Table 2 Association between prevalence of NCD risk factors and ART status
Risk Both n (%) Patients on ART, n (%) Patients not on ART, n (%) χ2 P-value**
LDL (>2.6 mmol/l) 282/658(42.9) 173(61.3) 109(38.7) 13.68 p < 0.001
HDL (<1.03 mmol/l for Male, < 1.29 for Female) 473/658(71.9) 206(43.6) 267(56.4) 61.49 p < 0.001
TC (>6.2 mmo/l) 215/658(32.7) 154(71.6) 61(28.4) 44.3 p < 0.001
Triglycerides (≥2 mmol/l) 109/658(16.6) 73(67.0) 36(33.0) 10.18 0.001
Overweight/Obesity (BMI≥ 25 kg/m2) 175/671(26.2) 107(61.1) 68(38.9) 6.68 0.01
Waist circumference (male ≥94 cm/female >80 cm) 303/650(46.6) 116(38.3) 187(61.7) 15.83 p < 0.001
Aged >40 years 275/671(41.0) 174(63.3) 101(36.7) 20.67 p < 0.001
1Smoking 26/671(3.9) 10(38.5) 16(61.5) 2.22 0.99
2Alcohol 221/671(32.9) 106(48.0) 115(52.0) 3.04 0.048
Consumed vegetables/fruits <5 days in a week 470/671(70.0) 240(51.1) 230(48.9) 1.81 0.104
3Never participate on vigorous intensity activity 321/671(47.8) 168(52.3) 153(47.7) 0.04 0.448
**Comparison between patients on ART and those not on ART.
1Smoking: Current tobacco users (smoke and smokeless tobacco users).
2Alcohol: Used alcohol in the last 12 months.
3Never participate on vigorous intensity activity: included not participating on running, cycling, digging, manual construction works, brisk working).
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of fruits or vegetables below the recommended standard
days per week, poor participation on vigorous physical
activities, abnormal waist circumference and raised
blood levels of LDL. Further, findings from this study
showed that NCDs risk factors were more prevalent
among PLWHIV on ART than those not ART. This
could partly be due to the effects of the ART drugs itself,
as some of the ART drugs, for example, stavudine hasTable 3 Multivariate logistic regression analysis to assess rela
risk factors among HIV positive patients utilizing CTC service
Risk factor Patients
COR
1Smoking 2.40(0.68-8.46)
2Alcohol 1.26(0.78-2.03)
Consumed vegetables/fruits <5 days in a week 0.79(0.49-1.28)
3Never participate on vigorous intensity activity 1.43(0.90-2.25)
LDL (>2.6 mmol/l) 1.46(0.92-2.32)
Aged >40 years 3.20(1.97-5.18) 3.4
HDL (<1.03 mmol/l Male, < 1.29 Female) 1.06(0.66-1.69)
Triglycerides (≥2 mmol/l) 1.96(1.22-3.16)
Waist circumference (male ≥94 cm/female >80 cm) 1.64(1.03-2.62)
Overweight/Obesity (BMI ≥ 25 kg/m2) 1.95(1.21-3.16)
Sex (Male) 0.87(0.53-1.42)
TC (>6.2 mmo/l) 2.01(1.26-3.20) 2.2
−2LR
Common odds ratio 3.3
*P-Value for AOR, 1Smoking: Current tobacco users (smoke and smokeless tobacco
1Smoking: Current tobacco users (smoke and smokeless tobacco users).
2Alcohol: Used alcohol in the last 12 months.
3Never participate on vigorous intensity activity: included not participating on runnbeen linked with raised blood levels of TG, LDL-C and
raised TC [15,16]. Moreover, all PIs except atazanavir
have been associated with hyperlipidemia. For example
ritonavir-boosted PIs, has been associated with elevated
blood levels of LDL, TC and TGs and a decrease in
HDL-C [17,18]. Effect of ART on the blood lipids levels
was also observed in study conducted in Uganda, in
which, low blood levels of HDL was observed in 60% of
patients on ART, raised blood levels of TC on 39% andtionship between prevalence of hypertension and NCD
s
not on ART Patients on ART
AOR P-value* COR AOR P-value*
1.20(0.37-3.85)
1.27(0.74-2.17)
0.84(0.47-1.51)
0.71(0.41-1.22)
1.42(0.81-2.47)
2(2.06-5.70) p < 0.001 2.59(1.50-4.49) 2.52(1.37-4.63) 0.003
1.79(0.71-4.44)
0.94(0.49-1.83)
2.86(1.64-5.00) 2.37(1.13-5.00) 0.023
3.85(2.14-6.93) 2.71(1.26-5.84) 0.011
1.52(0.85-2.70) 1.17(1.02-4.20) 0.043
8(1.39-3.75) 0.001 0.86(0.43-1.72)
24.19 p < 0.001 45.97 0.001
4(2.00-5.58) 2.37(1.31-4.31)
users).
ing, cycling, digging, manual construction works, brisk working).
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ively [39]. In South Africa the prevalence of obese/over-
weight among PLWHIV was observed to be 33% and
58% before and after initiation of ART respectively [40].
On the other hand, advanced age by itself is also asso-
ciated with NCDs. This could have also contributed on
the higher prevalence of NCD risk factors among study
participants on ART compared to those not on ART.
This is because this analysis showed that participants
aged above 40 years were more among those on ART
than their counterparts. Various studies conducted else-
where on PLWHIV have reported aging as a traditional
and remerging NCD risk factor and especially after initi-
ation of ART since PLWHIV are surviving longer up to
the NCD risk age level [41-43].
Findings from this analysis showed that the prevalence
of hypertension was significantly higher among partici-
pants on ART (30%) as compared to those not on ART
(21.9%). Similar findings were observed in Nigeria where
there was an increase of the prevalence of hypertension
from 26% to 31.7% after two years of ART initiation
[22]. The high prevalence of the disease among partici-
pants on ART may be due to the observed excessive risk
factors like raised blood levels of LDL, TC, triglyceride,
overweight/obesity and advanced age (i.e. >40 years)
among this group than their counterparts. Similar obser-
vations have been reported in other studies, in which ad-
vanced age, overweight and obesity, and abnormal waist
circumference, among PLWHIV who are on ART, have
been associated with hypertension [20,44]. Furthermore,
the ARTs are associated with heart diseases by increas-
ing blood levels of cholesterol and changing fat distribu-
tion, particularly increasing abdominal fat [12-14].
However, the prevalence of hypertension of 26.2% ob-
served in our study among patients on ART is lower
compared with 45% that was observed in Malaysia [44].
In this analysis, the prevalence of DM was slightly high
among participants not on ART compared to those on
ART (4.7% vs 3.7%). This observation is different from
the observations reported from other studies, in which
the prevalence of DM was reported to be more among
patients on ART compared to those not on ART
[39,45,46]. However, participants on ART in our study
may need to be followed up and assessed on their status
of DM in the future, as such risk factors as, prevalence
of hypertension, raised blood levels of LDL, TC, and tri-
glycerides as well as overweight, obesity and abnormal
waist circumference, all of which are also the risk fac-
tors for DM, were observed more among participants
on ART than those not on ART. Further, with efforts to
expand HIV programmes services, PLWHIV are initi-
ated on ART, consequently they are living longer and
ageing, and are developing non-HIV-related chronic
conditions similar to the rest of the population [42,43].Lastly, in this study no further analysis i.e. Univariate
and Multivariate analysis were conducted to establish
relationship between diabetes mellitus and associated
risk factors because the number of observed cases of
diabetes was small.
Conclusion
This study revealed that the prevalence of hypertension
and diabetes mellitus among PLWHIV was high. The
prevalence of hypertension was significantly higher
among participants on ART than those not on ART.
Majority of the NCD risk factors including raised blood
levels of LDL, TC and triglyceride also other risk factors
were abnormal waist circumference, overweight/obesity
and advanced age (i.e. >40 years) were more prevalent
among patients on ART than those not on ART. Based on
these findings, we recommend the initiation and strength-
ening of interventions on health education and awareness
creation on NCDs and NCD risk factors at each CTC. We
also recommend regular monitoring and screening for
NCD and risk factors to PLWHIV attending CTC for early
detection of NCDs and NCDs risk factors to prevent HIV-
NCDs co-morbidities and mortality. Continuous monitor-
ing and screening of PLWHIV at CTC will also provide
evidence to programme managers and policy makers to
inform planning and decision making.
Limitations of the study
Our study design was cross sectional, which is strong to
establish associations but weak in generating causal rela-
tionship between variables [47]. We therefore did not in-
clude causal relationships as this requires longitudinal
cohort study design. In this study, univariate and multi-
variate analysis to establish relationship between diabetes
and associated risk factors was not conducted because
the number of observed cases was small. This may have
affected the quality and the impact of the intended mes-
sage of our study. Furthermore, during data analysis we
encountered the problem of missing data especially the
biochemical data. This was associated with poor turn-up
in the next day of the interview for the biochemical test
even though the participants were assured of return fare.
In addition, the study ended up with moderate response
rate of 89% and is presumed to be contributed by pa-
tients who were not on ART as they tended to refrain
from taking part into the study in claim that they did
not have time. They considered that they did not require
extra services as compared to their counterparts who
were on ART. Lastly, the study lacked equal gender rep-
resentation as more than two quarters (70.5%) of the
study respondents were female. However, challenges
including gender norms around masculinity and sexual-
ity, confidentiality problems, self stigma and fearing of
community stigma and discriminations were the most
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ing care and treatment services in many countries in-
cluding Tanzania [48,49].
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